Published by IRDiRC
EU Planned Cross-Border TreatmentPatient InformationEarly Access SupportOrphan DrugResearch and Drug DevelopmentDifferent ways to access the health care structures and professionals of the foreign EU Country National Health System (NHS) for people insured in the EU countries.
View this resource Bookmark this resourcePublished by IRDiRC
Research and Drug DevelopmentRegulatory AffairsEarly Access SupportScientific AdviceStakeholder EngagementHealthcare ProfessionalThe Agency has been interacting with its stakeholders since its inception. These stakeholder relations have evolved over time and the type and degree of interaction is varied depending on the stakeholder groups and fields of Agency activity.
View this resource Bookmark this resourcePublished by IRDiRC
Paediatric MedicineEuropean Network of Paediatric ResearchResearch and Drug DevelopmentRegulatory AffairsOrphan DrugEarly Access SupportThe European Network of Paediatric Research at the European Medicines Agency (Enpr- EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Enpr-EMA enables networking and collaboration with members from within and outside the European Union (EU), including academia and the pharmaceutical industry
View this resource Bookmark this resourcePublished by IRDiRC
Regulatory AffairsResearch and Drug DevelopmentEMA Compassionate UseClinical DevelopmentOrphan DrugEarly Access SupportEuropean UnionCompassionate UseCompassionate use is a treatment option that allows the use of an unauthorised medicine. Under strict conditions, products in development can be made available to groups of patients who have a disease with no satisfactory authorised therapies and who cannot enter clinical trials.
View this resource Bookmark this resource
